ProQR Therapeutics NV reports results for the quarter ended in September - Earnings Summary

ProQR Therapeutics NV

09/11/2022 13:50

* ProQR Therapeutics NV  PRQR.OQ  reported a quarterly
adjusted
loss of 34 cents​​ per share for the quarter ended in September.
The mean expectation of seven analysts for the quarter was for a
loss of 21 cents per share.
    * Revenue fell 17.4% to €956.00 thousand from a year ago;
analysts
expected €838.99 thousand. 
    * ProQR Therapeutics NV's reported EPS for the quarter was a
loss
of 34 cents​.
    * The mean earnings estimate of analysts had risen by
about 3.8%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * ProQR Therapeutics NV shares had risen by 24.2% this
quarter and
lost 88.5% so far this year.
    * The company reported a quarterly loss of €24.4 million.
    * Wall Street's median 12-month price target for ProQR
Therapeutics NV is $1.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
9 at 01:50 p.m.  ​All figures in euros unless otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.21          -0.34          Missed
 Jun. 30 2022      -0.22          -0.21          Beat
 Mar. 31 2022      -0.24          -0.20          Beat
 Dec. 31 2021      -0.19          -0.26          Missed